Evgen Pharma Share Discussion Threads

[nobbygnome] 21/1/2021 11:52

Just bought some more; I feel a second surge today coming on....

[nobbygnome] 21/1/2021 11:50

For some reason there are always big sellers whenever there is even a small rise and it has been that way for many months. I just don't get it and would love to k ow who is selling.

[lovewinshatelosses] 21/1/2021 11:48

Extraordinary that we did not at least touch on year highs after that RNS, let alone where the share price is likely to end up today.
I reckon we could announce that a bid has been tabled for the company at a quid a share, cash offer, and still finish the day flat or red!
This is a most frustrating share to hold...

[peanut100] 21/1/2021 09:01

Should be closer to £100m than £16m that's for sure

[hodhasharon] 21/1/2021 08:50

The Twiterati are calling for 100p. Is today's news that positive?

[njb67] 21/1/2021 08:47

Have taken a position here after the news this morning.

[moneymunch] 21/1/2021 08:14

Most certainly peanut, we could have a flow of very good news on multiple targets in the coming weeks and months....true and fair value will prevail which could be transformational with any luck. Gl ;-)

[peanut100] 21/1/2021 08:04

Wait until they come out with the breast cancer news ???

[moneymunch] 21/1/2021 07:45

"Sulforaphane is a naturally occurring Nrf2 activator noted for its anti-inflammatory mechanisms and ability to quickly cross the blood-brain-barrier. "

[moneymunch] 21/1/2021 07:42

All you need to know about Glioblastoma, which has severely limited therapeutic options, and so let's hope SFX-01's compelling pre-clinical data has a a part to play. Gla ;-)


Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions

......................

Summary

Although there has been important progress in understanding the molecular pathogenesis and biology of glioblastoma, this has not translated into significantly improved outcomes for patients. While much remains to be learned, important therapeutic strategies have been identified that are being translated clinically. In addition to developing novel therapies based on strong scientific rationale, there is a need to increase the efficiency with which they are evaluated in clinical trials. This includes greater inclusion of glioblastoma patients in phase I oncology trials, an expanded network for conducting “window-of-opportunity” “phase 0” surgical studies to assess BBB penetration and pharmacodynamic effects, greater incorporation of molecular imaging and blood and CSF biomarkers, integration of a broad range of molecular biomarkers into clinical trial schema, more efficient design of clinical trials, and significantly increased trial accrual. These changes will hopefully lead to the identification of more effective therapies for patients with glioblastoma.

[nobbygnome] 21/1/2021 07:37

Winterfloods straight on to the 11p bid so looks promising.

[bumpa33] 21/1/2021 07:26

mm - should the ‘special one’ be on here in a flash to tell us why it’ll never work, do us all a favor and filter him this time...? Please!

[nobbygnome] 21/1/2021 07:25

Good data as far as it goes; let's hope it causes the lift off we are all waiting for. It will be somewhat ironic if some preclinical data provides the boost when a clinical trial does not!

[bumpa33] 21/1/2021 07:22

It’s a huge growing market, with currently largely unmet need - as per the RNS.

[bumpa33] 21/1/2021 07:11

That’s more like it. Well done Evgen.

[mesquida] 21/1/2021 07:08

Stand by for lift off. !

[albert arthur] 21/1/2021 07:03

https://www.londonstockexchange.com/news-article/EVG/positive-pre-clinical-data-for-lead-asset-sfx-01/14834738

[moneymunch] 21/1/2021 07:02

Positive pre-clinical data for lead asset SFX-01

RNS Number : 3802M
Evgen Pharma PLC
21 January 2021


Evgen Pharma plc

("Evgen" or the "Company")



Positive pre-clinical data in Glioma for lead asset SFX-01



Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, announces that its collaboration with a prominent European university has generated highly positive data for SFX-01 in pre-clinical models of glioma and glioblastoma.



Glioma is the most common form of brain tumour affecting around 5 per 100,000 people. The more severe, grade IV classification, glioblastoma, is a very serious form of brain tumour representing 45% of all cases and has a poor prognosis with median survival of around 14 months. The five-year survival of the severe grades is 5%.



The data generated for SFX-01 in standard pre-clinical models and orthotopic models (where glioma cells are implanted in brain tissue representing a more disease-relevant model) show tumour shrinkage and significantly extended survival times. SFX-01 was also found to potentiate (i.e. substantially increase) the therapeutic effect of radiotherapy in these models.



The therapeutic options for glioma are limited to surgery, radiotherapy and the one drug widely available, temozolomide. There is a clear unmet need for more treatments for use in conjunction with the current standard of care.



Dr Huw Jones, Evgen CEO, commented: "We are excited by this compelling new data in a type of cancer which has severely limited therapeutic options for the patient. The positive tolerability profile of SFX-01 makes it a viable option for use in addition to current treatments. Our plan is to expand upon these pre-clinical data in this and new collaborations, and start the process of designing an appropriate Phase II clinical trial."

[peanut100] 20/1/2021 22:45

And yes don't disagree but the start of that news was last sept and still nothing.

[notknowing] 20/1/2021 22:30

Don't assume COVID has been and gone. No boat has been missed. GDR have a huge US deal in the pipeline. Whispers will start in the next few days. The chart says we're still about three weeks away from the whoosh.

[peanut100] 20/1/2021 22:08

Hope they go up for new investors from here but so many and you've been burned I guess. Good luck but I'd rather take the loss and look somewhere like EVG to make those bad losses back as can't see GDR ever getting back to my cost let alone a profit

[peanut100] 20/1/2021 21:51

No disrespect but I feel you should suggest others on GDR thread buy EVG not us GDR. I had them and took a huge loss and won't look back at that woeful company and CEO. GDR holders may get their losses back here. How can you have a testing kit in Covid times and not sell one unit. Boat and missed springs to mind. They Raised money at huge discount when price went up. EVG holders be aware of this as thats what the broker does for fees.

[bumpa33] 20/1/2021 19:40

Rb. Well spotted. Amateur hour.